Value Communication

Communicating the Value of our Clients’ brands is where all the evidence and planning comes together. Our world-class Value Communication services with proprietary tools and processes, proven over many years in many therapy areas, are designed to develop, test and train the materials and capabilities required to communicate the value of the brand to Payer customers, Policy Makers and budget holders in an inspired and compelling way, so that patients gain access to the treatments they need.

Services

Why Partner with GalbraithWight

  • The global Strategic Market Access Consultancy with 20 years thought leadership partnering Pharma and Biotech Clients.
  • Experts in value strategy based on in-depth customer insights, creating value through clinical and HEOR evidence, achieving successful pricing, reimbursement and funding approval, brand launch and commercialisation, from discovery to loss of exclusivity.
  • Unparalleled expertise in building market access and commercial capabilities from foundation to expert level for global, regional and country teams, training thousands of managers from over 70 countries across five continents.
  • Highly expert team with extensive senior level strategic and operational international experience in major Pharma companies, who know and understand how to embed and operationalise our solutions in complex organisations and cross-functional teams, delivered on the ground throughout North and South America, Europe, Asia, Middle East and Africa.

What Our Clients Say

  • The training days were dynamic, energetic and fun to be a part of, and most of all productive in increasing our capability in this area.

    Associate Director – Market AccessSanofi Pasteur MSD
  • Overall training that changes behaviour. Gold standard. I can truly and honestly recommend all concerned as professional, trustworthy and highly skilled.

    Head of DermatologyGSK
  • For Payer strategy, positioning with payers, market landscape research, value story creation and message testing, absolutely would recommend.

    Senior DirectorAstraZeneca